Skip to main content
. 2020 Jan 22;10(2):190. doi: 10.3390/nano10020190

Figure 4.

Figure 4

Schematic overview of the events that alter the pharmacokinetics of repeated intravenous (IV) doses of pegylated liposomes. The first dose of pegylated liposomes stimulates the production of anti-PEG IgM antibodies by B cells within the spleen. This leads to the accelerated blood clearance of subsequent doses, during which circulating anti-PEG IgMs bind to the liposomes, initiating classical complement activation and decreasing blood circulation half-life.